Newsletter
Vallon Pharmaceuticals Gets Ahead of Itself
The sudden rise in the company's stock price on no news raises questions
Justin Hibbard
Justin Hibbard is a Certified Public Accountant, a Certified Fraud Examiner, and a licensed Private Investigator. Before starting Shortfinder, he was an examiner at FINRA.
Newsletter
How Warrants Work
Warrants are useful currency for issuers but potentially dilutive to shareholders
Newsletter
A Singular Diluter
An overhang of warrants and convertibles plagues Singularity Future Technology Ltd.
Newsletter
BIMI International Medical, Inc. Is in a Death Spiral
The Chinese healthcare company has a toxic dependency on convertible debt
Newsletter
How Dilution Works
Understanding dilution is essential to avoiding losses and picking stocks to sell short
Newsletter
Shares of TSR, Inc. Soar while Company Has ATM Offering
Dilution will put pressure on stock price as newly issued shares hit the market
Newsletter
G Medical Innovations Holdings Ltd. (NASDAQ:GMVD)
Impending dilution will put pressure on this stock
Newsletter
Aspire Capital Partners
How equity lines of credit can destabilize small-cap stock prices
Newsletter
Alpha Capital Anstalt
A Liechtenstein hedge fund with a penchant for dilution
Newsletter
Masters of Dilution (Part 2)
Enveric Biosciences, Inc. (ENVB) Is Issuing Shares Faster than It's Developing Drugs
Newsletter
Masters of Dilution
Enveric Biosciences, Inc. (ENVB) Is Issuing Shares Faster than It's Developing Drugs